Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2018–2022

Tumor-Treg-Targeting · Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2018-06-01 → 2022-11-30
EU contribution
€1,273,934
Participants
8
Scheme
MSCA-ITN

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Tumour-Treg-Targeting is a collaborative research and training project established to provide innovative and comprehensive training in antibody-based drug design to next-generation scientists in academia and industry in order to enable them to develop the next generation of antibody-based biologicals targeting and shifting the immunological environment specifically within tumours. These next-generation antibodies are designed to exploit all the potential of the immune system to fight cancer. The project addresses the following main goals: Objective 1: to develop novel biologicals that can target cell populations - such as cancerous cells or specific subtypes of leukocytes - with unprecedented specificity. Objective 2: to specifically engage particular cell types of the innate immune system within tumours with applied biologicals in a directed fashion. Objective 3: to target known immune-modulating cytokines or known check-point inhibitors directly into established tumours.

Data: CORDIS, © European Union

Project objective

Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just afew years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploitthe immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application withgreat success. The clinical application of these so called “check-point inhibitors”, however, is accompanied by severe sideeffects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmetneed. This proposal will employ the newest developments in antibody design to target the next generation of biologics righttowards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able tospecifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncanceroustissues unaffected, and thus diminish treatment associated side-effects.The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologistswith that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. Thisgroup will lead a training network that aims at educating a new generation of researchers, who will be able to bridge theinnovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, onthe other hand, the efficient translation and clinical validations of these findings in patients.

Original text from CORDIS.

Participants

  • UNIVERSIDAD DE NAVARRA · PamplonaCoordinatorSpain
  • ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
  • ADURO BIOTECH EUROPE BV · OssCity levelNetherlands
  • FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA · PamplonaSpain
  • ONENA MEDICINES SL · SAN SEBASTIANSpain
  • THE UNIVERSITY OF EDINBURGH · EdinburghUnited Kingdom
  • UNIVERSITEIT UTRECHT · UtrechtNetherlands
  • iOMEDICO AG · FreiburgGermany

Links

Data: CORDIS, © European Union